RhoVac ApS | LinkedIn
  • enEnglish
  • svSvenska
  • Start
  • Om oss
    ▼
    • Om ChosaOncology AB
    • Styrelse
    • Team
    • Vision och strategi
  • Produkt
    ▲
    • iCIP™
    • LiPlaCis®
    • DRP®
    • Vetenskapliga artiklar
    • Patent
  • Investerare
    ▼
    • Extra bolagsstämma 2023
    • Finansiella rapporter
      ▼
      • Chosa Oncology
      • Rhovac
    • Företrädesemission
    • Presentationer
    • Aktieinformation
    • Eventkalender
    • Bolagsstyrning
  • Nyheter
    ▼
    • Nyheter
    • Prenumerera
  • Kontakt
RhoVac AB - Logotype
  • Start
  • Om oss
    • Om ChosaOncology AB
    • Styrelse
    • Team
    • Vision och strategi
  • Produkt
    • iCIP™
    • LiPlaCis®
    • DRP®
    • Vetenskapliga artiklar
    • Patent
  • Investerare
    • Extra bolagsstämma 2023
    • Finansiella rapporter
      • Chosa Oncology
      • Rhovac
    • Företrädesemission
    • Presentationer
    • Aktieinformation
    • Eventkalender
    • Bolagsstyrning
  • Nyheter
    • Nyheter
    • Prenumerera
  • Kontakt
  • RHOVAC 1.39 (0)

Produkt

  • iCIP™
  • LiPlaCis®
  • DRP®
  • Vetenskapliga artiklar
  • Patent

Vetenskapliga artiklar

Kappel Buhl, I. et al.
Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
PloS One 2018; 10.1371

Hugger Jacobsen, E et. al.
Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study
Journal of Clinical Oncology, 2018, e13077

Kappel Buhl, I. et. al.
Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer
Abstract no.: e20007, ASCO Annual Meeting, Chicago, 2016

Lassen et. al.
Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumor
Cancer Research 76 (14 supplement), July 2016

 


Kontakta oss

Besöksadress: Medicon Village, Scheeletorget 1, Lund, Sverige | Postadress: Medicon Village AB, SE-223 81 Lund, Sverige | Org.nr: 559037-2271

073-751 72 78 info@chosa.bio


RhoVac has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 879817.


Cookiepolicy © 2015-2023 Chosa Oncology AB Alla rättigheter förbehålles